Tempest Q1 2023 net loss $7.6M ($0.55/shr); positive TPST-1120 HCC data highlighted

Tempest Therapeutics, Inc.

2023-Q1 EPS reported -$0.55

Net loss $7.6M ($0.55 per share) vs $8.5M ($1.18) in Q1 2022; cash $22.9M, runway through Q2 2024.
TPST-1120 in first-line HCC: unconfirmed ORR 30% (12/40) vs 17.2% control, 74.4% relative improvement.
Confirmed ORR 17.5% (7/40) vs 10.3% control, 69.9% relative improvement; 80% TPST-1120 arm on study vs 50% control.
TPST-1495 enrolling endometrial cancer arm with pembrolizumab; TREX1 inhibitor preclinical data presented at AACR.
Expects updated TPST-1120 data from Roche; plans to report TPST-1495 data at ASCO 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Tempest Therapeutics, Inc. reported quarter ended March 31, 2023 results: net income Net loss and net loss per share for the quarter ended March 31, 2023 were $7.6 million and $0.55, respectively, EPS $0.55.

Period: quarter ended March 31, 2023
Net income: Net loss and net loss per share for the quarter ended March 31, 2023 were $7.6 million and $0.55, respectively
EPS: $0.55
Result: reported results

Exact text from the filing

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class i therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended March 31, 2023

View on SEC.gov

49 earnings releases filed in the last 30 days. Browse all earnings releases →

Tempest Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-020569

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.